Efficacy and Tolerability of Brevilin-A, a Natural JAK Inhibitor, in Pediatric Alopecia Areata: A Case Series

October 2024 in “ Clinical Cosmetic and Investigational Dermatology ”

Enrico Matteini, Laura Diluvio, Sara Lambiase, Arnaldo Cioni, Ruslana Gaeta Shumak, Gaetana Costanza, Caterina Lanna, Giacomo Caldarola, Luca Bianchi, Elena Campione

Brevilin-A JAK inhibitor alopecia areata Centipeda minima JAKs tyrosine kinase STAT3 STAT1 JAK inhibitors

Studysummary This study documented successful use of Brevilin-A, a topical treatment, in pediatric patients with alopecia areata, indicating it as a potentially safe and effective option for managing mild-moderate cases and resistant forms of the disease.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

This study assessed the efficacy and tolerability of Brevilin-A, a natural JAK inhibitor, in 15 pediatric patients with mild-moderate alopecia areata over 6 months. Patients applied a topical lotion containing Brevilin-A, leading to significant hair regrowth and improved quality of life, with 46.7% achieving complete lesion resolution and 33.3% showing partial improvement. No significant adverse events were reported. Despite the small sample size and absence of a control group, Brevilin-A shows promise as a treatment for recalcitrant alopecia areata in children, potentially offering an alternative to traditional therapies with fewer side effects. Further research is needed to confirm these findings.

View this study on dovepress.com →

Discuss this study in the Community →

Research cited in this study

10 / 10 results

research Effect of Baricitinib in Patients with Alopecia Areata: Usefulness of Trichoscopic Evaluation

5 citations , December 2023 in “Journal of the European Academy of Dermatology and Venereology”

research Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial

227 citations , April 2023 in “The Lancet”

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

research Quality of Life in Children and Adolescents With Alopecia Areata: A Systematic Review

39 citations , January 2023 in “Journal of the European Academy of Dermatology and Venereology”

This review found that alopecia areata significantly impairs quality of life, particularly through embarrassment and self-consciousness, in children and adolescents.

Impact of Pediatric Alopecia Areata on Quality of Life of Patients and Their Family Members: A Nationwide Multicenter Questionnaire Study

research Impact of Pediatric Alopecia Areata on Quality of Life of Patients and Their Family Members: A Nationwide Multicenter Questionnaire Study

17 citations , January 2022 in “Annals of Dermatology”

In this study, the severity of pediatric alopecia areata was found to decrease the quality of life for both patients and their families while increasing the overall burden.

research Treatment of Pediatric Alopecia Areata: A Systematic Review

48 citations , April 2021 in “Journal of the American Academy of Dermatology”

This study found that topical corticosteroids are the most supported first-line treatment for pediatric alopecia areata, with contact immunotherapy as the next best option.

research Hair Growth Effect of Emulsion Extracted Brevilin A, a JAK3 Inhibitor, from Centipeda Minima

15 citations , June 2020 in “Processes”

This study suggests that the emulsion extract of brevilin A from Centipeda minima may stimulate hair regrowth in individuals with mild to moderate vertex balding by inhibiting JAK3.

research Alopecia Areata: A Long-Term Follow-Up Study of 104 Patients

29 citations , March 2019 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”

This study found that the severity, duration, and relapse rate of alopecia areata decreased with older age at onset, while relapses mostly occurred early and declined over time.

research JAK Inhibitors for Treatment of Alopecia Areata

63 citations , July 2018 in “The journal of investigative dermatology/Journal of investigative dermatology”

In this review, the researchers reported that JAK inhibitors, originally approved by the FDA for other uses, have shown effectiveness in reversing hair loss in patients with moderate to severe alopecia areata, based on current preclinical and clinical studies.

research Topical Janus Kinase Inhibitors for the Treatment of Pediatric Alopecia Areata

83 citations , June 2017 in “Journal of the American Academy of Dermatology”

This study observed that most pediatric patients with alopecia areata experienced some hair regrowth after treatment with topical JAK inhibitors, and the formulations were generally well-tolerated with mild lab abnormalities in some cases.

research Clobetasol Propionate, 0.05%, vs Hydrocortisone, 1%, for Alopecia Areata in Children

49 citations , November 2013 in “JAMA dermatology”

This study found that topical clobetasol propionate cream was more effective than hydrocortisone cream in reducing hair loss surface area in children with patchy alopecia areata over 24 weeks, with no serious adverse effects.